IVISense™ Cat B FAST fluroescent probes enable non-invasive in vivo detection of disease status and progression in oncology, inflammation and other areas associated with Cat B activity.
Associated with tumor aggression, cathepsins are a family of proteases that are pivotal components of signaling pathways that can enhance cancer cell growth and inflammation. Within the human lysosomal cysteine cathepsin family, there are 11 members, including cathepsin B, L, S, and Plasmin. As a family, cysteine cathepsins are involved in the response to anticancer therapy within the tumor microenvironment and play crucial roles in the development of resistance to therapeutics. In particular, cathepsin B expression correlates with the invasive and metastatic capabilities of many tumors, such as in breast cancer where high expression levels of cathepsin B have been linked to highly aggressive tumors. Cathepsin B is also upregulated in a variety of inflammatory cells (including eosinophils, neutrophils, and macrophages).
true falseFor research use only. Not for use in diagnostic procedures.
IVISense Cat B 750 FAST is a Cathepsin B activatable fluorescent probe that is optically silent upon injection and produces fluorescent signal after cleavage by Cathepsin B produced by inflammatory cells and tumor cells. IVISense Cat B 750 FAST may be used to monitor inflammation, tumor activity, progression of disease and the efficacy of therapeutic treatment in applications such as oncology, inflammation, cardiovascular disease and some neurological diseases.
IVISense Cat B 750 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background.
| Fluorescent Agent Type | Activatable |
|---|---|
| Optical Imaging Classification | Fluorescence Imaging |
| Product Brand Name | IVISense |
| Quantity in a Package Amount | 1.0 Units |
| Shipping Condition | Ambient |
| Therapeutic Area | Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer |
| Unit Size | 1 Vial (10 doses) |
| Wave Length | 750 nm |
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles asso ...
Non-alcoholic fatty liver disease (NAFLD) describes a progressive pathology that affects the liver. Fat accumulation causes fatty liver (NAFL) or steatosis to develop, which leads to lipotoxicity and in turn induces liver inflammation and apoptosis, resulting in non-alcoholic steatohepatitis (NAS ...
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best p ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation ...
Cat B 750 FAST activatable fluorescent imaging protocol
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...
IVISense Vascular Fluorescent Imaging Panel
List Price : USD2565.0
IVISense Arthritis Fluorescent Imaging Panel
List Price : USD2922.0
